Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 14, 2022 9:08pm
196 Views
Post# 34684440

RE:RE:RE:does she know something, the rest of you don't?

RE:RE:RE:does she know something, the rest of you don't?
Doccole wrote:

I am def excited about end of summer.  

I do believe everything is in play now that Cita will be unloaded.

advancing the pipe line and increasing value- would be lovely.

NASDQ uplist going into phase 2 vs at the end would be interesting.  

Look forward to updates and increased MC.




Yes - I look at the sale of CITAGENIX as letting go of the safety blanket.

This is the final move in creating a drug development pure-play and we've waiting a long time to realize it.

Here are the key moves over the past 2 years ...

1.  Reverse split completed - reduced share count
2.  Purchased Holdings Inc. assets for the equivalent of ~6M shares
3.  Cashed up to ensure we have funds to move development/negotiations forward as needed
4.  Sale of CITAGENIX - confidence in the drug development path forward

That sets us up nicely to co-list when the time is right.

The cash in the bank allows us to move in a variety of drug development directions and to promote the development of gaseous mediator technology.  It also gives us the ability to utilize specialists to solve complex problems going forward.

I suggest the pause was "heaven sent."
It couldn't have happened at a better time - and - we had many options/directions in dealing with it
Very hard to see right now but I think we are much stronger for it.
I know that's really hard to understand right now ... but ... better - stronger - faster !!!

Stay tuned ... on the edge of my seat in 2022!

<< Previous
Bullboard Posts
Next >>